What can we do to promote the growth acceralation of micropremie babies in order to prevent extrauterin growth retardation?

Essential interventions to accelerate the growth of micropremie babies and prevent extrauterine growth retardation: 
Ensure optimal maternal nutrition. 
Early trophic feeding and quick advancement of the dose and diversity, including more fortified foods.
Parenteral nutrition of highly energized, protein-rich foods.
Regular growth and development monitoring.
Infection control.
Skin to skin contact.

The anti-aging gene Sirtuin 1 is critical to the prevention of growth and growth retardation. Sirtuin 1 is important to brain development and the prevention of multiple organ disease syndrome. The activation of Sirtuin 1 will promote growth acceleration of micropremie babies. The consumption of Sirtuin 1 activators versus inhibitors  are important to growth acceleration of to the prevention of micropremie babies. 

RELEVANT REFERENCES:

1.      Anti-Aging Genes Improve Appetite Regulation and Reverse Cell Senescence and Apoptosis in Global Populations. Advances in Aging Research, 2016, 5, 9-26

2.      Nutrition Therapy Regulates Caffeine Metabolism with Relevance to NAFLD and Induction of Type 3 Diabetes. J Diabetes Metab Disord. 2017; 4: 019.

3.      Single Gene Inactivation with Implications to Diabetes and Multiple Organ Dysfunction Syndrome. J Clin Epigenet. 2017;Vol. 3 No. 3:24.

4.      Sirtuin 1, a Diagnostic Protein Marker and its Relevance to Chronic Disease and Therapeutic Drug Interventions”. EC Pharmacology and Toxicology 6.4 (2018): 209-215.

I believe that genetic testing is a part and parcel of the management of extremely preterm infants, particularly given the increasing recognition of the contribution of genetic illnesses towards intrauterine and postnatal growth retardation.

Sometimes the baby is delivered preterm because there is an underlying genetic condition that affect the infant or the placenta.

Early-onset multisystem illnesses, a few of which may initially manifest as failure to thrive or refractoriness to usual nutrition management, may often be accounted for by focused or pan-spectrum genetic investigation (eg, rapid exome or genome sequencing). In neonates with unconventional clinical courses or adverse response to optimized nutrition and medical treatment, early genetic diagnosis can uncover covert metabolic, syndromic, or neurodevelopmental illness that might otherwise have gone unnoticed.

The clinical utility of a genetic diagnosis is twofold. On the one hand, in the setting of severe, progressive, and currently untreated conditions, such as some mitochondrial disorders, neurodegenerative syndromes, or syndromic skeletal dysplasias, early diagnosis can allow for shared decision-making about goals of care. Under these circumstances, clinicians and families may choose to steer the agenda away from cure-based, potentially burdensome, and non-beneficial treatments and toward optimization of comfort and quality of life. On the other hand, for many other conditions such as congenital glycosylation diseases, metabolic diseases, or syndromes with disease-specific surveillance guidelines—a definitive genetic diagnosis facilitates institution of disease-specific therapy, early supportive management, and individualized follow-up. This approach not only improves clinical outcomes but can prevent iatrogenic damage and improve resource utilization.